Skip to main content

Thyroid health- Quality of Life

 






Let's get a TSH blood test for our family and friends

Normal serum TSH ranges are higher in the people age 70 to 80 years; based on this, higher serum TSH goals may be needed as a patient ages. 

The American Thyroid Association (ATA) suggests raising the target serum TSH to 4-6 m IU/L for 70 years-old and up

The thyroid is a small, butterfly-shaped hormone-producing gland located at the front of the neck. The thyroid gland secretes two main hormones: 

thyroxine (T-4) and triiodothyronine (T-3). 

These hormones regulate energy levels, metabolism of fats, proteins and carbohydrates, body temperature, heart rate. 

Hypothyroidism happens when the underactive thyroid gland doesn't make enough hormones.

Hypothyroidism affects up to 10% of the general population (5% undiagnosed). An autoimmune disease called Hashimoto's disease where our body  makes antibodies that attack healthy thyroid tissues is the most common cause of hypothyroidism in societies with enough iodine consumption . Thyroid gland damage occurs when sensitized T-lymphocytes and/or autoantibodies bind to thyroid cell membranes causing inflammation and breaking them. 

Symptoms of hypothyroidism are non-specific and include mild to moderate weight gain, lack of interest, fatigue, poor concentration, depression, and menstrual irregularities. Consequences of untreated or under-treated hypothyroidism may include low quality of health, cardiovascular disease and increased mortality.

Hypothyroidism is diagnosed by a simple blood test, where a patient has serum thyroid-stimulating hormone (TSH) concentrations above and thyroxine concentrations below the normal reference range.

Levothyroxine has long been the main medication for managing hypothyroidism and is one of the world’s most widely prescribed medicines. (cost range: $4-$15 based on dose for 30 days supply). Liothyronine at Olive/Carethera pharmacies is $12 for 30 days supply with prescription.

Adult dose: levothyroxine is usually prescribed at a starting dose of 1.6 µg/kg/day, which is then titrated to achieve therapeutic range TSH levels (0.4–4.0 mIU/L). The American Thyroid Association (ATA) suggests raising the target serum TSH to 4-6 mIU/L in 

References:

1. Chiovato L, Magri F, Carlé A. Hypothyroidism in Context: Where We've Been and Where We're Going. Adv Ther. 2019 Sep;36(Suppl 2):47-58. doi: 10.1007/s12325-019-01080-8. Epub 2019 Sep 4. PMID: 31485975; PMCID: PMC6822815.

2. https://pro.endocrineweb.com/hypothyroidism/american-thyroid-association-guidelines-treatment-hypothyroidism

3. https://www.thyroid.org/ (accessed 01/27/2023)

Comments

Popular posts from this blog

Mounjaro, Is it a game changer for weight loss and diabetes?

  MOUNJARO™ ( Tirzepatide) was approved for medical use in the United States in May 2022 WEIGHT LOSS: (Not approved by FDA for weight loss) Eli Lilly and Company is  finalizing an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management. MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in adults for type 2 diabetes mellitus management. CONTRAINDICATIONS Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2  Known serious all to tirzepatide or any of the excipients in MOUNJARO                                                                    ...

Heart healthy

*Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin. Should I initiate statins or not? The 2014 National Lipid Association (NLA) recommendations provides a more comprehensive, patient-centered approach to identifying ASCVD risk.   In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) issued guidelines to use the intensity of statin therapy as the treatment goal instead of LDL-C or non–HDL-C targets, as in previous guidelines, to reduce atherosclerotic cardiovascular disease (ASCVD) risk (  Andrus & Lacaille, 2014  )  The guideline classifies statin therapy as  high-intensity (lowers LD...